Dolat Capital: Trump’s Executive Orders On Drug Pricing Comes With Many Caveats; Neutral For Indian Pharma
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
On July 24, the U.S. President Donald Trump issued four Executive Orders on prescription drug pricing which are expected to bring down generics prices and restructure the entire prescription drug market. The orders are as follows:
1) Lowering prices for patients by eliminating kickbacks to middlemen
2) Increasing drug importation to lower prices
3) Access to affordable life-saving medications – insulins and Epipens
4) Adoption of international pricing for Medicare.
This order has been delayed up to August 24, 2020 to provide the industry an opportunity to negotiate contract prices.
The orders do not contain any major new policy changes. Most of the policy changes were included in the Department of Health and Human Services blueprint to lower drug prices and reduce out of pocket expenses released in May 2018. Further, the orders come with certain caveats which might prevent its implementation specially the last order on drug pricing
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.